Moderate riskFDA DrugClass II

Harbin Jixianglong semaglutide recalled for incomplete manufacturing validation

Harbin Jixianglong Biotech distributed semaglutide (an injectable medication for compounding) without completing required manufacturing process and bacterial endotoxin testing. This means the drug may not meet safety and purity standards. The affected lot is CP-030-20250711 with an expiration date of July 24, 2027.

From the FDA notice · Read the official notice ↗

What to do

  1. If you have semaglutide from Harbin Jixianglong with lot CP-030-20250711, stop using it immediately.
  2. Contact your pharmacist or healthcare provider for guidance on next steps.
  3. Do not discard medication in the trash or toilet; ask your pharmacy how to safely dispose of it.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China
Sold in
Nationwide
Made for
All ages (0 months and older)

This recall covers 2 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
North Of Baoan Road, East Of Changqing Street, Hulan District, Haerbin, N/A, China
Classification
Class II
Recall number
D-0379-2026

In the FDA's words

Description
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution Lot #: CP-030-20250711, Exp. Date Jul. 24th, 2027 Distribution: Nationwide within the United States Affected quantity: N/A
Hazard
CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

2 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

OtherDrugsSold nationwideMore from FDA Drug